Pharmaceutical

Oracle Recognized as a Leader in Everest Group PEAK Matrix® for Life Sciences Clinical Trial Management System (CTMS) Assessment 2024

Highlights ease of deployment, value, and extensibility of comprehensive Oracle platform ORLANDO, Fla. , Feb. 3, 2025 /PRNewswire/ -- SCOPE 2025 – Oracle…

11 months ago

IgniteData Expands EHR-to-EDC Capabilities with Yunu Integration for Imaging Data in Clinical Trials

WILMINGTON, Del., Feb. 3, 2025 /PRNewswire/ -- IgniteData, a leader in EHR-to-EDC interoperability for clinical trials, has partnered with Yunu…

11 months ago

Procaps Group Receives Delisting Notice From Nasdaq

MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…

11 months ago

Procaps Group Receives Delisting Notice From Nasdaq

MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…

11 months ago

Procaps Group Receives Delisting Notice From Nasdaq

MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…

11 months ago

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety…

11 months ago

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety…

11 months ago

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety…

11 months ago

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

11 months ago

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

11 months ago